Search Results - "Massidda B"

Cancer patients as `experts' in defining quality of life domains. A multicentre survey by the Italian Group for the Evaluation of Outcomes in Oncology (IGEO).

Authors: Costantini, M. Mencaglia, E. Giulio, P. D. et al.

Source: Quality of Life Research. Feb2000, Vol. 9 Issue 2, p151-159. 9p.

Subjects: Health surveys, Cancer patients, Quality of life, Oncology

Geographic Terms: Italy

Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study.

Authors: Comella, P. Massidda, B. Palmeri, S. et al.

Source: Cancer Chemotherapy & Pharmacology. Nov2005, Vol. 56 Issue 5, p481-486. 6p.

Cancer patients as 'experts' in defining quality of life domains. A multicentre survey by the Italian Group for the Evaluation of Outcomes in Oncology (IGEO).

Authors: Costantini, M Mencaglia, E Giulio, P D et al.

Source: Quality of Life Research. Mar2000, Vol. 9 Issue 3, p151-159. 9p.

Cholesterol esters as growth regulators of lymphocytic leukaemia cells.

Authors: Mulas, M. F. Abete, C. Pulisci, D. et al.

Source: Cell Proliferation. Aug2011, Vol. 44 Issue 4, p360-371. 12p. 1 Color Photograph, 1 Chart, 7 Graphs.

Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC).

Authors: Di Costanzo, F. Carlini, P. Doni, L. et al.

Source: British Journal of Cancer. 7/25/2005, Vol. 93 Issue 2, p185-189. 5p.

Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients.

Authors: Comella, P. Frasci, G. Carnicelli, P. et al.

Source: British Journal of Cancer. 8/2/2004, Vol. 91 Issue 3, p489-497. 9p. 1 Diagram, 6 Charts, 3 Graphs.

Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients.

Authors: Ruzzo, A Graziano, F Galli, Fabio et al.

Source: British Journal of Cancer. 10/24/2017, Vol. 117 Issue 9, p1269-1277. 9p. 6 Charts, 1 Graph.

Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study.

Authors: Roila, F. Ruggeri, B. Ballatori, E. et al.

Source: Annals of Oncology. Jun2015, Vol. 26 Issue 6, p1248-1253. 6p. 4 Charts.

Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Long term results of the Italian Tamoxifen Anastrozole trial

Authors: Boccardo, F. Guglielmini, P. Bordonaro, R. et al.

Source: European Journal of Cancer. May2013, Vol. 49 Issue 7, p1546-1554. 9p.

A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study.

Authors: Vici, P. Brandi, M. Giotta, F. et al.

Source: Annals of Oncology. May2012, Vol. 23 Issue 5, p1121-1129. 9p. 3 Diagrams, 4 Charts, 1 Graph.

Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial.

Authors: Cognetti, F. Ruggeri, E. M. Felici, A. et al.

Source: Annals of Oncology. Mar2012, Vol. 23 Issue 3, p695-700. 6p. 3 Charts, 2 Graphs.

Attitude of Italian medical oncologists toward palliative care for patients with advanced cancer: results of the SIO project.

Authors: Barni S Maltoni M Tuveri G et al.

Source: Supportive Care in Cancer. Mar2011, Vol. 19 Issue 3, p381-389. 9p.

Weekly Docetaxel and Gemcitabine as First-Line Treatment for Metastatic Breast Cancer: Results of a Multicenter Phase II Study.

Authors: Palmeri, S. Vaglica, M. Spada, S. et al.

Source: Oncology. 2005, Vol. 68 Issue 4-6, p438-445. 8p. 5 Charts, 1 Graph.

Nestin expression associates with poor prognosis and triple negative phenotype in locally advanced (T4) breast cancer.

Authors: Piras F Ionta MT Lai S et al.

Source: European journal of histochemistry : EJH [Eur J Histochem] 2011 Nov 14; Vol. 55 (4), pp. e39. Date of Electronic Publication: 2011 Nov 14.

Publication Type: Journal Article

Journal Info: Publisher: PagePress Publications Country of Publication: Italy NLM ID: 9207930 Publication Model: Electronic Cited Medium: Internet ISSN: 2038-8306 (Electronic) Linking ISSN: 1121760X NLM ISO Abbreviation: Eur J Histochem Subsets: MEDLINE

Efficacy and tolerability of biweekly bevacizumab, irinotecan, folinic acid and fluorouracil intravenous bolus (BIFF Regimen) in patients with metastatic colorectal cancer: the southern Italy cooperative oncology group experience.

Authors: Comella P Massidda B Natale D et al.

Source: Clinical colorectal cancer [Clin Colorectal Cancer] 2011 Mar 01; Vol. 10 (1), pp. 42-7.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101120693 Publication Model: Print Cited Medium: Internet ISSN: 1938-0674 (Electronic) Linking ISSN: 15330028 NLM ISO Abbreviation: Clin Colorectal Cancer Subsets: MEDLINE

Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy.

Authors: Ruzzo A Graziano F Galli F et al.

Source: Scientific reports [Sci Rep] 2020 Jan 31; Vol. 10 (1), pp. 1918. Date of Electronic Publication: 2020 Jan 31.

Publication Type: Published Erratum

Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE; PubMed not MEDLINE

Molecular alterations in key-regulator genes among patients with T4 breast carcinoma.

Authors: Massidda B Sini M Budroni M et al.

Source: BMC cancer [BMC Cancer] 2010 Aug 24; Vol. 10, pp. 458. Date of Electronic Publication: 2010 Aug 24.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy.

Authors: Ruzzo A Graziano F Galli F et al.

Source: Scientific reports [Sci Rep] 2019 Aug 08; Vol. 9 (1), pp. 11527. Date of Electronic Publication: 2019 Aug 08.

Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Equivalence Trial

Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Targeting insulin-like growth factor type 1 receptor in cancer therapy.

Authors: Atzori F Traina TA Ionta MT et al.

Source: Targeted oncology [Target Oncol] 2009 Dec; Vol. 4 (4), pp. 255-66. Date of Electronic Publication: 2009 Oct 30.

Publication Type: Journal Article; Review

Journal Info: Publisher: Springer-Verlag France Country of Publication: France NLM ID: 101270595 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1776-260X (Electronic) Linking ISSN: 17762596 NLM ISO Abbreviation: Target Oncol Subsets: MEDLINE

Long-term outcomes in stage IIIB breast cancer patients who achieved less than a pathological complete response (<pCR) after primary chemotherapy.

Authors: Ionta MT Atzori F Deidda MC et al.

Source: The oncologist [Oncologist] 2009 Nov; Vol. 14 (11), pp. 1051-60. Date of Electronic Publication: 2009 Nov 06.

Publication Type: Journal Article

Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE